Emerging ADCs and Their Role in Advanced Lung Cancer Treatment-Emerging ADCs and Their Role in Advanced Lung Cancer Treatment

Video Transcription

Video Summary

In this webinar, the presenters discussed emerging antibody-drug conjugates (ADCs) and their role in advanced lung cancer treatment. ADCs are a new class of drugs that consist of an antibody attached to a cytotoxic drug via a linker. The structure and mechanism of action of ADCs were explained, as well as the future development opportunities for these drugs. It was mentioned that ADCs have the potential to increase the therapeutic index by delivering a higher dose of cytotoxic drug to the tumor while reducing systemic toxicity. However, the clinical validation of these concepts is still ongoing. Several FDA-approved ADCs were highlighted, and it was mentioned that there are more than 400 ADCs currently in development. The importance of patient selection was emphasized, and factors such as target antigen properties, antibody properties, and drug-antibody ratio were discussed. The potential for rational combinations with existing standard of care treatments, such as chemotherapy, immunotherapy, and anti-VEGF therapies, was also mentioned. The presentation concluded by acknowledging the challenges and opportunities in ADC drug development, including optimizing patient selection, managing side effects, and exploring rational combinations for enhanced efficacy and overcoming resistance. Overall, the webinar provided an overview of the current state of ADCs and their potential future directions in lung cancer treatment.

Keywords

webinar

antibody-drug conjugates

ADCs

lung cancer treatment

cytotoxic drug

linker

therapeutic index

clinical validation

FDA-approved ADCs

development opportunities